TY - JOUR
T1 - Intermediate renal outcomes, kidney failure, and mortality in obese kidney donors
AU - Ibrahim, Hassan N.
AU - Murad, Dina N.
AU - Hebert, Sean A.
AU - Adrogue, Horacio E.
AU - Nguyen, Hana
AU - Nguyen, Duc T.
AU - Matas, Arthur J.
AU - Graviss, Edward A.
N1 - Funding Information:
A. Matas reports receiving research funding from Alexion, CareDX, CSL Behring, Shire, and Veloxis; and reports being a scientific advisor to or member of Jazz. H. E. Adrogue reports having an ownership interest in Dialyspa Dialysis Unit Houston Texas; and Speakers Bureau from Astra-Zeneca and Care DX. H.N. Ibrahim reports having consultancy agreements with Novartis; reports receiving research funding from the National Institutes of Health; reports receiving honoraria from Relypsa; and reports being a scientific advisor to or member of Exosome Diagnostics. All remaining authors have nothing to disclose.
Publisher Copyright:
Copyright ß 2021 by the American Society of Nephrology
PY - 2021/11
Y1 - 2021/11
N2 - Background Obesity is associated with the two archetypal kidney disease risk factors: hypertension and diabetes. Concerns that the effects of diabetes and hypertension in obese kidney donors might be magnified in their remaining kidney have led to the exclusion of many obese candidates from kidney donation. Methods We compared mortality, diabetes, hypertension, proteinuria, reduced eGFR and its trajectory, and the development of kidney failure in 8583 kidney donors, according to body mass index (BMI). The study included 6822 individuals with a BMI of <30 kg/m2, 1338 with a BMI of 30–34.9 kg/m2, and 423 with a BMI of >35 kg/m2. We used Cox regression models, adjusting for baseline covariates only, and models adjusting for postdonation diabetes, hypertension, and kidney failure as time-varying covariates. Results Obese donors were more likely than nonobese donors to develop diabetes, hypertension, and proteinuria. The increase in eGFR in obese versus nonobese donors was significantly higher in the first 10 years (3.5 ml/min per 1.73m2 per year versus 2.4 ml/min per 1.73m2 per year; P<0.001), but comparable thereafter. At a mean6SD follow-up of 19.3610.3 years after donation, 31 (0.5%) nonobese and 12 (0.7%) obese donors developed ESKD. Of the 12 patients with ESKD in obese donors, 10 occurred in 1445 White donors who were related to the recipient (0.9%). Risk of death in obese donors was not significantly increased compared with nonobese donors. Conclusions Obesity in kidney donors, as in nondonors, is associated with increased risk of developing diabetes and hypertension. The absolute risk of ESKD is small and the risk of death is comparable to that of nonobese donors.
AB - Background Obesity is associated with the two archetypal kidney disease risk factors: hypertension and diabetes. Concerns that the effects of diabetes and hypertension in obese kidney donors might be magnified in their remaining kidney have led to the exclusion of many obese candidates from kidney donation. Methods We compared mortality, diabetes, hypertension, proteinuria, reduced eGFR and its trajectory, and the development of kidney failure in 8583 kidney donors, according to body mass index (BMI). The study included 6822 individuals with a BMI of <30 kg/m2, 1338 with a BMI of 30–34.9 kg/m2, and 423 with a BMI of >35 kg/m2. We used Cox regression models, adjusting for baseline covariates only, and models adjusting for postdonation diabetes, hypertension, and kidney failure as time-varying covariates. Results Obese donors were more likely than nonobese donors to develop diabetes, hypertension, and proteinuria. The increase in eGFR in obese versus nonobese donors was significantly higher in the first 10 years (3.5 ml/min per 1.73m2 per year versus 2.4 ml/min per 1.73m2 per year; P<0.001), but comparable thereafter. At a mean6SD follow-up of 19.3610.3 years after donation, 31 (0.5%) nonobese and 12 (0.7%) obese donors developed ESKD. Of the 12 patients with ESKD in obese donors, 10 occurred in 1445 White donors who were related to the recipient (0.9%). Risk of death in obese donors was not significantly increased compared with nonobese donors. Conclusions Obesity in kidney donors, as in nondonors, is associated with increased risk of developing diabetes and hypertension. The absolute risk of ESKD is small and the risk of death is comparable to that of nonobese donors.
UR - http://www.scopus.com/inward/record.url?scp=85119058986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119058986&partnerID=8YFLogxK
U2 - 10.1681/ASN.2021040548
DO - 10.1681/ASN.2021040548
M3 - Article
C2 - 34675059
AN - SCOPUS:85119058986
VL - 32
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
SN - 1046-6673
IS - 11
ER -